Gewinn- und Verlustrechnung von Ionis Pharmaceuticals, Inc.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31 in Munich. Presentations include one-year data from the open-label, long-term extension study of TRYNGOLZA® (olezarsen), recently approved in the U.S. as the first and only treatment for sHTG to reduce triglycerides and the risk o.

Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report.

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv

LOS ANGELES--(BUSINESS WIRE)---- $IONS--IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law.

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

20,000 shares were purchased for a total value of ~$1.1 million across multiple execution windows. The acquisition increased the director's total direct and indirect equity holdings by 34%.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) Director Michael Hayden purchased 15,000 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, July 30th. The shares were acquired at an average cost of $53.38 per share, for a total transaction of $800,700.00. Following the transaction, the director directly owned 19,000 shares of the company's

Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.